Drug Detail:Sorafenib (Sorafenib [ sor-a-fen-ib ])
Drug Class: Multikinase inhibitors VEGF/VEGFR inhibitors
Sorafenib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of sorafenib during breastfeeding. Because sorafenib is 99.5% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 25 to 48 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sorafenib therapy and for 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Sorafenib
CAS Registry Number
284461-73-0
Drug Class
-
Breast Feeding
-
Lactation
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Protein Kinase Inhibitors
-
Signal Transduction Inhibitors
-
Tyrosine Kinase Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification